Coronavirus disease 2019 and mechanical circulatory support devices: A comprehensive review
UMass Chan AffiliationsMedicine
Document TypeAccepted Manuscript
left ventricular assist device (LVAD)
extracorporeal membrane oxygenation (ECMO)
intra aortic balloon pump (IABP)
MetadataShow full item record
AbstractCoronavirus disease (COVID-19) can cause circulatory shock refractory to medical therapy. Such patients can be managed with mechanical circulatory support (MCS) devices like IABP, Impella, VA ECMO, and Left Ventricular Assist Devices (LVADs). Moreover, patients on long-term durable LVADs are a special population having increased susceptibility and mortality to COVID-19 infection. In this narrative review, we searched PubMed and Medline for studies on COVID-19 patients on short-term MCS devices. We found 36 papers with 110 patients who met our review criteria, including 89 LVAD patients and 21 COVID-19 patients who needed MCS device therapy. These studies were used to extract patient demographics, clinical presentation, MCS device details, management, and outcomes. Mean age of patients with COVID-19 infection on LVADs was 60, 73% were male, and HeartMate 3 was the most common device (53%). Most patients (77.5%) needed hospitalization, and mortality was 23.6%. Among the 21 reported cases of critically ill COVID-19 patients who required MCS, the mean age was 49.8 years, 52% were women, and the most common MCS device used was VA ECMO (62%) in conjunction with an Impella for LV venting. Comorbidities were not present in 43%, but 71% had abnormal ventricular function on echocardiography. MCS is a viable option for managing severe COVID-19 infection with shock, with many reported cases of favorable outcomes.
SourceJohn K, Mishra AK, Nayar J, Mehawej J, Lal A. Coronavirus disease 2019 and mechanical circulatory support devices: A comprehensive review. Monaldi Arch Chest Dis. 2022 Sep 5. doi: 10.4081/monaldi.2022.2362. Epub ahead of print. PMID: 36063088.
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/51203
RightsCopyright (c) 2022 The Author(s). This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.; Attribution-NonCommercial 4.0 International
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Copyright (c) 2022 The Author(s). This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.; Attribution-NonCommercial 4.0 International